Leiomyosarcoma of the uterus

Corscaden, James A.; Singh, Bohar

doi:10.1016/0002-9378(58)90563-5

“…The 5-year survival in Aaro and Dockerty's series was 4601,l while, at the other extreme, Corscaden and Singh report but one cure in 32 leiomyosarcomas. 6 Analysis of the survival vs. the non-survival group (Tables 11, 12) reveals a difference in age distribution. Only 3 of 11 patients in the "cured" group exceeded 50 years of age when diagnosed.…”

Section: Results Of Therapy In the Primary Treatment Groupmentioning

confidence: 99%

“…All ployed except in rare instances and has not been significant in the experience of others. 6 There is considerable disparity in the survival figures which have been reported from different institutions. The 5-year survival in Aaro and Dockerty's series was 4601,l while, at the other extreme, Corscaden and Singh report but one cure in 32 leiomyosarcomas.…”

Section: Results Of Therapy In the Primary Treatment Groupmentioning

confidence: 99%

Myosarcoma of the uterus.A Clinicopathological Study

Spiro

¹

,

Koss

²

1965

Cancer

View full text Add to dashboard Cite

“…The use of anti-VEGF-A antibodies to treat leiomyomas should therefore be explored. It would be interesting to investigate whether these agents would reduce the rare neoplastic progression of leiomyoma to leiomyosarcoma, which occurs in less than 0.1 % of cases [27,28]. In a recent case report [25], a large uterine leiomyoma was observed to shrink by 90 % in a woman treated for hepatitis with interferon, an antiangiogenic agent [26].…”

Section: Discussionmentioning

confidence: 99%

Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium

Gentry

¹

,

Okolo

²

,

Fong

³

et al. 2001

View full text Add to dashboard Cite

Although uterine leiomyomas constitute the commonest benign tumour in women, the regulation of their growth is poorly understood. It is believed that angiogenesis, the process by which new capillaries develop from pre-existing blood vessels, may be involved. We therefore investigated the expression of vascular endothelial growth factor-A (VEGF-A), a primary regulator of angiogenesis, in leiomyoma tissue and the adjacent myometrium in 36 pre-menopausal women undergoing hysterectomy for leiomyomas, with or without prior treatment with gonadotrophin-releasing hormone analogue (GnRHa). In 5 microm sections prepared from archival paraffin-wax blocks, VEGF-A was demonstrated by standard immunohistochemistry using a monoclonal antibody. VEGF-A was expressed in 14 of 18 (77.8%) leiomyoma sections from women without GnRHa pretreatment, and in 15 of 18 (83%) of those from women with prior treatment. VEGF-A expression in the adjacent myometrium was much lower, being noted in two of 18 (11.1%) sections from women without prior GnRHa treatment and in one of 18 (5.5%) sections from tissue that had been subject to prior down-regulation. Moreover, when VEGF-A expression was present, expression was strong in leiomyomas (> or =20 focal areas/cm(2)), but not in adjacent myometrium. The differential expression of VEGF-A antigen in leiomyomas compared with the adjacent myometrium indicates that local angiogenesis may be important in the development and growth of these tumours. GnRHa therapy does not appear to alter this pattern of VEGF-A expression.

show abstract

“…This shrinkage persisted at 17 months after cessation of interferon therapy. It would be interesting to investigate whether these agents would reduce the rare neoplastic progression of leiomyoma to leiomyosarcoma, which occurs in less than 0.1 % of cases [27,28].…”

Section: Discussionmentioning

confidence: 99%

Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium

GENTRY

¹

,

Okolo

²

,

FONG

³

et al. 2001

View full text Add to dashboard Cite

Although uterine leiomyomas constitute the commonest benign tumour in women, the regulation of their growth is poorly understood. It is believed that angiogenesis, the process by which new capillaries develop from pre-existing blood vessels, may be involved. We therefore investigated the expression of vascular endothelial growth factor-A (VEGF-A), a primary regulator of angiogenesis, in leiomyoma tissue and the adjacent myometrium in 36 pre-menopausal women undergoing hysterectomy for leiomyomas, with or without prior treatment with gonadotrophin-releasing hormone analogue (GnRHa). In 5 microm sections prepared from archival paraffin-wax blocks, VEGF-A was demonstrated by standard immunohistochemistry using a monoclonal antibody. VEGF-A was expressed in 14 of 18 (77.8%) leiomyoma sections from women without GnRHa pretreatment, and in 15 of 18 (83%) of those from women with prior treatment. VEGF-A expression in the adjacent myometrium was much lower, being noted in two of 18 (11.1%) sections from women without prior GnRHa treatment and in one of 18 (5.5%) sections from tissue that had been subject to prior down-regulation. Moreover, when VEGF-A expression was present, expression was strong in leiomyomas (> or =20 focal areas/cm(2)), but not in adjacent myometrium. The differential expression of VEGF-A antigen in leiomyomas compared with the adjacent myometrium indicates that local angiogenesis may be important in the development and growth of these tumours. GnRHa therapy does not appear to alter this pattern of VEGF-A expression.

show abstract

Leiomyosarcoma of the uterus

Cited by 41 publications

References 8 publications

Myosarcoma of the uterus.A Clinicopathological Study

Myosarcoma of the uterus.A Clinicopathological Study

Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium

Quantification of vascular endothelial growth factor-A in leiomyomas and adjacent myometrium

Contact Info

Product

Resources

About